New pill aims to tackle stubborn cholesterol

NCT ID NCT06834932

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is testing a new oral medication called AZD0780 to see if it can safely and effectively lower 'bad' cholesterol (LDL-C) in people with dyslipidemia. The trial will involve about 360 adults in China, some already on standard cholesterol treatments and some not. Participants will take the drug or a placebo for up to a year to compare results.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Baotou, 14010, China
Research Site
RECRUITING

Beijing, 100029, China
Research Site
RECRUITING

Beijing, 100050, China
Research Site
RECRUITING

Bengbu, 233004, China
Research Site
RECRUITING

Changchun, 130021, China
Research Site
RECRUITING

Changchun, 130033, China
Research Site
RECRUITING

Changde, 415000, China
Research Site
RECRUITING

Changsha, 410015, China
Research Site
RECRUITING

Changzhou, 272100, China
Research Site
RECRUITING

Chengdu, 610000, China
Research Site
RECRUITING

Chongqing, 402260, China
Research Site
RECRUITING

Daqing, 163000, China
Research Site
RECRUITING

Deyang, 618000, China
Research Site
RECRUITING

Guangzhou, 510100, China
Research Site
RECRUITING

Guangzhou, 510220, China
Research Site
RECRUITING

Hengyang, 421001, China
Research Site
RECRUITING

Heze, 274099, China
Research Site
RECRUITING

Linhai, 317000, China
Research Site
RECRUITING

Luoyang, 471000, China
Research Site
RECRUITING

Nanchang, 330009, China
Research Site
RECRUITING

Nanchong, 637900, China
Research Site
RECRUITING

Nanjing, 210009, China
Research Site
RECRUITING

Pingxiang, 337055, China
Research Site
RECRUITING

Qiqihar, 161000, China
Research Site
RECRUITING

Sanya, 572000, China
Research Site
RECRUITING

Shanghai, 200032, China
Research Site
RECRUITING

Shanghai, 200120, China
Research Site
NOT_YET_RECRUITING

Shanghai, 310000, China
Research Site
RECRUITING

Shenyang, 110004, China
Research Site
RECRUITING

Shenyang, 110016, China
Research Site
RECRUITING

Siping, 136000, China
Research Site
RECRUITING

Taiyuan, 030024, China
Research Site
RECRUITING

Tianjin, 300457, China
Research Site
RECRUITING

Wuhan, 430010, China
Research Site
RECRUITING

Wuhan, 430030, China
Research Site
RECRUITING

Wuhan, 430060, China
Research Site
COMPLETED

Xi'an, 710068, China
Research Site
RECRUITING

Xianyang, 750004, China
Research Site
RECRUITING

Yinchuan, 750004, China
Research Site
ACTIVE_NOT_RECRUITING

Zigong, 643021, China
Research Site
RECRUITING

Hong Kong, 999077, Hong Kong
Research Site
COMPLETED

Hong Kong, Hong Kong
Research Site
RECRUITING

Shatin, 00000, Hong Kong

Conditions

Explore the condition pages connected to this study.

DYSLIPIDAEMIA